983 Adverse Reaction Reports of Oxaliplatin

doi:10.19803/j.1672-8629.20240799

Abstract

Abstract: Objective To analyze the characteristics of adverse reactions caused by oxaliplatin in order to provide a reference for clinical safe drug use. Methods The ADR of oxaliplatin reported to the National Adverse Drug Reaction Monitoring System by a province between 2022 and 2023 were collected before signals were mined and analyzed using the reported odds ratio (ROR) method and the Medicines and Healthcare Products Regulatory Agency (MHRA) method. Results According to the 983 ADR reports of oxaliplatin, the age of the patients mostly ranged from 45 to 65, and most of the ADR occurred within 24 hours of medication. There were 275 cases (27.98%) serious ADR. The positive signals involved 9 systems-organs (SOC), and the top three preferred terms (PTs) were nausea, vomiting and bone marrow suppression. The top three PT signals were hyperhidrosis, dyspnea and itching. Conclusion Oxaliplatin has little chance of causing serious ADR or obvious ADR that affect preexisting diseases, but during or after infusion, hyperhidrosis, dyspnea and itching deserve special attention. There is the need to find out whether the ADR are allergies in order to offer quick interventions.

Key words: Oxaliplatin, Nausea, Vomiting, Bone Marrow Suppression, Hyperhidrosis, Dyspnea, Itching, Adverse Drug Reaction

CLC Number:

ZHAO Yufang, SHI Wei, YANG Shengnan, LIU Zhien, LEI Wenpu, ZHANG Yanan, ZHAO Ke, GUO Hao. 983 Adverse Reaction Reports of Oxaliplatin[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 645-648.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240799

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I6/645

References

[1] BRAY F, LAVERSANNE M, SUNG H, et al.Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA: a Cancer Journal for Clinicians, 2024, 74(3): 229-263.
[2] LU X, LU D, JIN ZJ, et al.Efficacy and Safety of Cindilizumab Combined with Chemotherapy in the Treatment of Advanced Gastric Cancer[J]. Clinical Medication Journal(临床药物治疗杂志), 2023, 21(11): 47-51.
[3] LUO Y, LU X, MA W, et al.Dampening HOTAIR Sensitizes the Gastric Cancer Cells to Oxaliplatin through miR-195-5p and ABCG2 Pathway[J]. Journal of Cellular and Molecular Medicine, 2023, 27(22): 3591-3600.
[4] Oncology Branch of Chinese Medical Association, Department of Medical Administration, National Health and Wellness Committee. Diagnostic and Therapeutic Guidelines for Colorectal Cancer in China (2023 Edition)[J]. Medical Journal of Peking Union Medical College Hospital(协和医学杂志), 2023, 14(4): 706-733.
[5] DEVANABANDA B, KASI A.Oxaliplatin[M]. Treasure Island (FL): StatPearls, 2023.
[6] KANG L, TIAN Y, XU S, et al.Oxaliplatin-Induced Peripheral Neuropathy: Clinical Features, Mechanisms, Prevention and Treatment[J]. Journal of Neurology, 2021, 268(9): 3269-3282.
[7] HE L, CHEN J, WANG SM, et al.Study on the Safety of Real-World Anti-Influenza Drugs Mabaloxavir and Oseltamivir[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2024, 44(8): 935-940.
[8] ZHAO B.Concerned about the Common Problems in the Research of ADR Signal Detection[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2023, 25(8): 449-453.
[9] CHEN F, HONG SX.Adverse Event Signal Mining of Infliximab Based on FAERS[J]. China Pharmaceuticals(中国药业), 2025, 34(3):114-119.
[10] YOU XY, ZHENG YY, WANG XY.Analysis of Adverse Event Signal Mining of Infliximab Based on FAERS Database[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2024, 21(3): 335-340.
[11] RUI XY, FENG XF, WEI CC, et al.Analysis of Esophageal Cancer Death Trend and Age-Period-Cohort Model in China from 2007 to 2021[J]. Chinese Journal of Cancer Prevention and Treatment(中华肿瘤防治杂志), 2025, 32(2): 70-77.
[12] LI W, XIAO L, YU ZQ, et al.Attention and Intervention of Oncologists on Oxaliplatin-Induced Adverse Reactions in Mainland China: a Cross-Sectional Internet-Based Survey[J]. Current Medical Science, 2022, 42(6): 1319-1324.
[13] GAO TY, TAO YT, LI HY, et al.Cancer Burden and Risk in the Chinese Population Aged 55 Years and Above: a Systematic Analysis and Comparison with the USA and Western Europe[J]. Journal of Global Health, 2024, 14: 04014.
[14] National Medical Products Administration on the Revision of Oxaliplatin Preparation Instructions Announcement[J]. Journal of China Prescription Drug(中国处方药), 2021, 19(9): 3.
[15] BROCKOW K, WURPTS G, TRAUTMANN A, et al.Guideline for Allergological Diagnosis of Drug Hypersensitivity Reactions: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) in cooperation with the German Dermatological Society (DDG), the Association of German Allergologists (ÄDA), the German Society for Pediatric Allergology (GPA), the German Contact Dermatitis Research Group (DKG), the German Society for Pneumology (DGP), the German Society of Otorhinolaryngology, Head and Neck Surgery, the Austrian Society of Allergology and Immunology (ÖGAI), the Austrian Society of Dermatology and Venereology (ÖGDV), the German Academy of Allergology and Environmental Medicine (DAAU), and the German Documentation Center for Severe Skin Reactions (dZh)[J]. Allergol Select, 2023, 7: 122-139.
[16] OKAYAMA T, ISHIKAWA T, SUGATANI K, et al.Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol[J]. Clinical Therapeutics, 2015, 37(6): 1259-1269.
[17] HUANG QX, TIAN X, HE SL, et al.Research Progress on the Mechanism of Abnormal Sweat Secretion in Atopic Dermatitis[J]. Chinese Journal of Laboratory Diagnosis(中国实验诊断学), 2021, 25(7): 1096-1099.
[18] KATOH N, OHYA Y, IKEDA M, et al.Japanese Guidelines for Atopic Dermatitis 2020[J]. Allergology International, 2020, 69(3): 356-369.
[19] XIA RN, YING T, LIANG H, et al.Signal Mining and Analysis of Acitinib ADE Based on FAERS Database[J]. China Pharmacy(中国药房), 2023, 34(23): 2896-2900.
[20] PARK G, JUNG H, HEO SJ, et al.Comparison of Data Mining Methods for the Signal Detection of Adverse Drug Events with a Hierarchical Structure in Postmarketing Surveillance[J]. Life-Basel, 2020, 10(8): 138.